Hennion & Walsh Asset Management, Inc. Immuno Gen, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 10, 2024	SELL	$12.46 - $29.95 $2.07 Million - $4.97 Million	-166,077 Reduced 31.75%	356,997 $10.6 Million
Q3 2023 Oct 27, 2023	BUY	$14.09 - $19.87 $109,831 - $154,886	7,795 Added 1.51%	523,074 $8.3 Million
Q2 2023 Aug 09, 2023	BUY	$3.75 - $20.05 $129,532 - $692,567	34,542 Added 7.19%	515,279 $9.72 Million
Q1 2023 Apr 20, 2023	BUY	$3.67 - $4.92 $40,737 - $54,612	11,100 Added 2.36%	480,737 $1.85 Million
Q4 2022 Jan 12, 2023	BUY	$4.55 - $6.31 $622,271 - $862,974	136,763 Added 41.09%	469,637 $2.33 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $105,459 - $152,303	23,540 Added 7.61%	332,874 $1.59 Million
Q2 2022 Jul 19, 2022	BUY	$3.15 - $5.76 $356,542 - $651,962	113,188 Added 57.71%	309,334 $1.39 Million
Q1 2022 Apr 26, 2022	BUY	$4.26 - $7.48 $329,839 - $579,153	77,427 Added 65.22%	196,146 $934,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $563,915 - $890,392	118,719 New	118,719 $881,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.